Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications

BACKGROUND: Evidence of the effectiveness of the WHO-recommended design of longer individualized regimens for multidrug- or rifampicin-resistant TB (MDR/RR-TB) is limited. OBJECTIVES: To report end-of-treatment outcomes for MDR/RR-TB patients from a 2015–2018 multi-country cohort that received a reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Rich, M. L., Khan, U., Zeng, C., LaHood, A., Franke, M. F., Atwood, S., Bastard, M., Burhan, E., Danielyan, N., Dzhazibekova, P. M., Gadissa, D., Ghafoor, A., Hewison, C., Islam, M. S., Kazmi, E., Khan, P. Y., Lecca, L., Maama, L. B., Melikyan, N., Naing, Y. Y., Philippe, K., Saki, N. A., Seung, K. J., Skrahina, A., Tefera, G. B., Varaine, F., Vilbrun, S. C., Võ, L., Mitnick, C. D., Huerga, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Union Against Tuberculosis and Lung Disease 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237267/
https://www.ncbi.nlm.nih.gov/pubmed/37231598
http://dx.doi.org/10.5588/ijtld.22.0613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237267/
https://www.ncbi.nlm.nih.gov/pubmed/37231598
http://dx.doi.org/10.5588/ijtld.22.0613

Ejemplares similares